ATE458735T1 - Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs - Google Patents

Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs

Info

Publication number
ATE458735T1
ATE458735T1 AT04776639T AT04776639T ATE458735T1 AT E458735 T1 ATE458735 T1 AT E458735T1 AT 04776639 T AT04776639 T AT 04776639T AT 04776639 T AT04776639 T AT 04776639T AT E458735 T1 ATE458735 T1 AT E458735T1
Authority
AT
Austria
Prior art keywords
pyridino
compounds
pyrimidine
cancer agent
alone
Prior art date
Application number
AT04776639T
Other languages
English (en)
Inventor
Weibo Wang
Ryan N Constantine
Liana M Lagniton
Sabina Pecchi
Matthew T Burger
Manoj C Desai
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE458735T1 publication Critical patent/ATE458735T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04776639T 2003-06-20 2004-06-17 Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs ATE458735T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48018003P 2003-06-20 2003-06-20
PCT/US2004/019158 WO2004113335A2 (en) 2003-06-20 2004-06-17 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents

Publications (1)

Publication Number Publication Date
ATE458735T1 true ATE458735T1 (de) 2010-03-15

Family

ID=33539266

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04776639T ATE458735T1 (de) 2003-06-20 2004-06-17 Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs

Country Status (15)

Country Link
US (1) US7326711B2 (de)
EP (1) EP1636225B1 (de)
JP (1) JP2007520435A (de)
KR (1) KR20060069356A (de)
CN (1) CN1809563A (de)
AT (1) ATE458735T1 (de)
AU (1) AU2004249730A1 (de)
CA (1) CA2528771A1 (de)
DE (1) DE602004025698D1 (de)
ES (1) ES2339862T3 (de)
IL (1) IL172192A0 (de)
MX (1) MXPA05013142A (de)
PT (1) PT1636225E (de)
TW (1) TW200503719A (de)
WO (1) WO2004113335A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964967B2 (en) * 2000-12-11 2005-11-15 Amgen, Inc. Substituted pyrido[2,3-d]pyrimidines and methods for their use
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
AU2004218080B2 (en) * 2003-03-07 2008-01-03 Astrazeneca Ab Novel fused heterocycles and uses thereof
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
US7572914B2 (en) * 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2556914A1 (en) * 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
PT1732926E (pt) 2004-04-06 2009-04-03 Novartis Vaccines & Diagnostic Inibidores de cinesinas mitóticas
EP1763524A1 (de) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Indolderivate und deren verwendung als kinaseinhibitoren
EP1773830A1 (de) * 2004-07-22 2007-04-18 AstraZeneca AB Für die behandlung und prävention von krebs geeignete kondensierte pyrimidone
BRPI0514390A (pt) * 2004-08-18 2008-06-10 Astrazeneca Ab enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
TW200718689A (en) * 2005-04-14 2007-05-16 Chiron Corp 2-Amino-quinazolin-5-ones
ATE474829T1 (de) 2005-06-27 2010-08-15 Amgen Inc Entzündungshemmende arylnitrilverbindungen
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2223925A1 (de) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
CA2674318A1 (en) 2007-01-05 2008-07-17 Novartis Ag Cyclized derivatives as eg-5 inhibitors
EP2448938B9 (de) * 2009-06-29 2015-06-10 Incyte Corporation Pyrimidinone als pi3k-hemmer
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP2558463A1 (de) 2010-04-14 2013-02-20 Incyte Corporation Kondensierte derivate als i3-hemmer
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR102030609B1 (ko) 2011-09-02 2019-10-11 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
JP6092897B2 (ja) * 2012-02-10 2017-03-08 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
EA029155B1 (ru) 2012-03-01 2018-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
CA2868026C (en) 2012-03-23 2021-02-16 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP3082820B1 (de) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Verfahren zur modulation der menge von rna-transkripten
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
DK3831833T3 (da) 2015-02-27 2022-11-14 Incyte Holdings Corp Fremgangsmåder til fremstillingen af en pi3k-inhibitor
RU2717665C2 (ru) * 2015-04-15 2020-03-24 Ф. Хоффманн-Ля Рош Аг Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
JP6749343B2 (ja) * 2015-05-20 2020-09-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 脊髄性筋萎縮症を処置するための化合物
EP4249472A3 (de) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Verfahren zur modulation von rna-spleissen
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
WO2018098446A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc Methods for modulating rna splicing
EP3634953B1 (de) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Verbindungen zur behandlung von morbus huntington
BR112019026508A2 (pt) 2017-06-14 2020-07-14 Ptc Therapeutics, Inc. métodos para modificar o splicing do rna
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN108191860B (zh) * 2018-02-12 2019-12-10 中国医科大学 一种HIF-2α小分子抑制剂及其用途
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
CN119258070A (zh) 2018-06-01 2025-01-07 因赛特公司 治疗pi3k相关病症的给药方案
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
EP3814360B8 (de) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl verbindungen zur behandlung von morbus huntington
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203913T1 (de) * 1993-05-31 2001-08-15 Kaken Pharma Co Ltd Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
GB2307177A (en) 1995-11-15 1997-05-21 Agrevo Uk Ltd Fungicidal pyridopyrimidines
BR0015110A (pt) 1999-10-27 2002-07-02 Cytokinetics Inc Métodos de tratamento de doenças de proliferação celular, de tratamento de um distúrbio associado com a atividade da cinesina ksp, de inibição da cinesina ksp, de triagem de moduladores da cinesina kps e de triagem de compostos que se ligam na cinesina ksp, e, compostos
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6964967B2 (en) 2000-12-11 2005-11-15 Amgen, Inc. Substituted pyrido[2,3-d]pyrimidines and methods for their use
EP1379554A2 (de) * 2001-02-21 2004-01-14 Curagen Corporation Proteine, dafür codierende polynukleotide und methoden unter verwendung davon
EP1444209A4 (de) * 2001-11-07 2005-02-16 Merck & Co Inc Inhibitoren mitotischer kinesine
JP4467979B2 (ja) * 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
JP2005515208A (ja) * 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂性キネシン阻害剤
WO2004064741A2 (en) * 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods

Also Published As

Publication number Publication date
EP1636225A2 (de) 2006-03-22
US20050085490A1 (en) 2005-04-21
ES2339862T3 (es) 2010-05-26
WO2004113335A2 (en) 2004-12-29
PT1636225E (pt) 2010-05-03
KR20060069356A (ko) 2006-06-21
DE602004025698D1 (de) 2010-04-08
CN1809563A (zh) 2006-07-26
AU2004249730A1 (en) 2004-12-29
MXPA05013142A (es) 2006-03-17
IL172192A0 (en) 2006-04-10
EP1636225B1 (de) 2010-02-24
US7326711B2 (en) 2008-02-05
WO2004113335A3 (en) 2005-03-24
CA2528771A1 (en) 2004-12-29
JP2007520435A (ja) 2007-07-26
TW200503719A (en) 2005-02-01

Similar Documents

Publication Publication Date Title
ATE458735T1 (de) Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs
ATE538103T1 (de) Chinazolinonverbindungen als antikrebsmittel
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
TNSN08143A1 (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-ones
BRPI0510560A (pt) pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos
WO2004006859A3 (en) Platinum compound
MY148583A (en) Pyridine [3,4-b] pyrazinones
FR13C0062I1 (de)
CA2603830A1 (en) PYRIDINE [2,3-B] PYRAZINONES
IL175716A (en) 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation
IS7857A (is) Setnar pýrróló-pýrasól afleiður sem kínasa hindrar
WO2009143156A3 (en) Imidazo [1, 2-a] pyridine compounds as gaba-a receptor modulators
GB0428475D0 (en) Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
WO2004087713A8 (en) Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
NO20062398L (no) Daglig, oral, kontrollert frigivnings oksycodon-doserings form
HRP20130459T1 (en) Topical co-enzyme q10 formulations and methods of use
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
GEP20105095B (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
EP1503748A4 (de) Arzneimittel zur linderung durch taxan induzierte neurotoxizität
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2002070515A3 (en) Chromane derivatives, process for their preparation and their use as antitumor agents
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
PH12012502122A1 (en) Imidazo[1,2-a]pyridine derivative

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties